Show simple item record

Authordc.contributor.authorYáñez, Osvaldo
Authordc.contributor.authorOsorio, Manuel Isaías
Authordc.contributor.authorUriarte, Eugenio
Authordc.contributor.authorAreche Medina, Carlos Alberto
Authordc.contributor.authorTiznado, William
Authordc.contributor.authorPérez Donoso, José M.
Authordc.contributor.authorGarcía Beltrán, Olimpo José
Authordc.contributor.authorGonzález Nilo, Fernando Danilo
Admission datedc.date.accessioned2022-01-10T21:09:25Z
Available datedc.date.available2022-01-10T21:09:25Z
Publication datedc.date.issued2021
Cita de ítemdc.identifier.citationFrontiers in Chemistry, February 2021, Volume 8, Article 595097es_ES
Identifierdc.identifier.other10.3389/fchem.2020.595097
Identifierdc.identifier.urihttps://repositorio.uchile.cl/handle/2250/183634
Abstractdc.description.abstractThe pandemic that started in Wuhan (China) in 2019 has caused a large number of deaths, and infected people around the world due to the absence of effective therapy against coronavirus 2 of the severe acute respiratory syndrome (SARS-CoV-2). Viral maturation requires the activity of the main viral protease (Mpro), so its inhibition stops the progress of the disease. To evaluate possible inhibitors, a computational model of the SARS-CoV-2 enzyme Mpro was constructed in complex with 26 synthetic ligands derived from coumarins and quinolines. Analysis of simulations of molecular dynamics and molecular docking of the models show a high affinity for the enzyme (ΔEbinding between −5.1 and 7.1 kcal mol−1). The six compounds with the highest affinity show Kd between 6.26 × 10–6 and 17.2 × 10–6, with binding affinity between −20 and −25 kcal mol−1, with ligand efficiency less than 0.3 associated with possible inhibitory candidates. In addition to the high affinity of these compounds for SARS-CoV-2 Mpro, low toxicity is expected considering the Lipinski, Veber and Pfizer rules. Therefore, this novel study provides candidate inhibitors that would allow experimental studies which can lead to the development of new treatments for SARS-CoV-2.es_ES
Patrocinadordc.description.sponsorshipMinistry of Education Ministry of Industry, Commerce and Tourism ICETEX, Programme Ecosistema Cientifico-Colombia Cientifica Francisco Jose de Caldas Fund RC-FP44842-212-2018 ANID/PIA/ACT192144es_ES
Lenguagedc.language.isoenes_ES
Publisherdc.publisherFrontiers Mediaes_ES
Type of licensedc.rightsAttribution-NonCommercial-NoDerivs 3.0 United States*
Link to Licensedc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/us/*
Sourcedc.sourceFrontiers in Chemistryes_ES
Keywordsdc.subjectSARS-CoV-2es_ES
Keywordsdc.subjectCoumarinses_ES
Keywordsdc.subjectQuinolineses_ES
Keywordsdc.subjectProteasees_ES
Keywordsdc.subjectMolecular dynamicses_ES
Títulodc.titleIn silico study of coumarins and quinolines derivatives as potent inhibitors of sars-cov-2 main proteasees_ES
Document typedc.typeArtículo de revistaes_ES
dc.description.versiondc.description.versionVersión publicada - versión final del editores_ES
dcterms.accessRightsdcterms.accessRightsAcceso abiertoes_ES
Catalogueruchile.catalogadorcfres_ES
Indexationuchile.indexArtículo de publícación WoSes_ES
Indexationuchile.indexArtículo de publicación SCOPUSes_ES


Files in this item

Icon

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivs 3.0 United States
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivs 3.0 United States